New developments around histamine H₃ receptor antagonists/inverse agonists: a patent review (2010 – present)

Bibliography

• Arrang JM, Garbarg M, Schwartz JC. Autoinhibition of brain histamine release mediated by a novel class (H3) receptor of histamine. Nature 1983;302:832-7
   PubMed Web of Science ®Google Scholar
• Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55:1101-7
   PubMed Web of Science ®Google Scholar
• Bakker RA. Histamine H3-receptor isoforms. Inflamm Res 2004;53:509-16
   PubMed Web of Science ®Google Scholar
• Hancock AA, Esbenshade TA, Krueger KM, Yao BB. Genetic aspects to pharmacological heterogeneity of histamine H3 receptors. Life Sci 2003;73:3043-72
   PubMed Web of Science ®Google Scholar
• Ireland-Denny L, Parihar AS, Miller TR, et al. Species-related pharmacological heterogeneity of histamine H3 receptors. Eur J Pharmacol 2001;433:141-50
   PubMed Web of Science ®Google Scholar
• Schnell D, Strasser A, Seifert R. Comparison of the pharmacological properties of human and rat histamine H3 receptors. Biochem Pharmacol 2010;80:1437-49
   PubMed Web of Science ®Google Scholar
• Arrang JM, Morisset S, Gbahou F. Constitutive activity of the histamine H3 receptor. Trends Pharmacol Sci 2007;28:350-7
   PubMed Web of Science ®Google Scholar
• Blandina P, Gioretti M, Bartolini L, et al. Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in rats. Br J Pharmacol 1996;119:1655-64
   Web of Science ®Google Scholar
• Jang IS, Rhee JS, Watanabe T, Akaide N. Histaminergic modulation of GABAergic transmission in rat ventromedical hypothalamic neurones. J Physiol 2001;534:791-803
   PubMed Web of Science ®Google Scholar
• Schlicker E, Werthwein S, Zentner J. Histamine H3 receptor-mediated inhibition of noradrenaline release in the human brain. Fundam Clin Pharmacol 1999;13:120-2
   PubMed Web of Science ®Google Scholar
• Schlicker E, Betz R, Gothert M. Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 1988;337:588-90
   PubMed Web of Science ®Google Scholar
• Schlicker E, Fink K, Detzner M, Gothert M. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect 1993;93:1-10
   PubMed Web of Science ®Google Scholar
• Hass HL, Sergeeva OA, Selbach O. Histamine in nervous system. Physiol Rev 2008;88:1183-241
   PubMed Web of Science ®Google Scholar
• Stark H, Kathmann M, Schlicker E, et al. Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists. Mini Rev Med Chem 2004;4:965-77
   PubMed Web of Science ®Google Scholar
• Stark H, Arrang JM, Ligneau X, et al. The histamine H3 receptor and its ligands. Prog Med Chem 2001;38:279-308
   PubMedGoogle Scholar
• Ganellin CR, Leurquin F, Piripitsi A, et al. Synthesis of potent non-imidazole histamine H3 receptor antagonists. Arch Pharm Pharm Med Chem 1998;331:395-404
   PubMed Web of Science ®Google Scholar
• Lebois EP, Jones CK, Lindsley CW. The evolution of histamine H3 antagonists/inverse agonists. Curr Top Med Chem 2011;11:648-60
   PubMed Web of Science ®Google Scholar
• Berlin M, Boyce CW, Ruiz Mde L. Histamine H3 receptor as a drug discovery target. J Med Chem 2011;54:26-53
   PubMed Web of Science ®Google Scholar
• Raddatz R, Tao M, Hudkins RL. Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem 2010;10:153-69
   PubMed Web of Science ®Google Scholar
• Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31:2163-81
   PubMed Web of Science ®Google Scholar
• Singh M, Jadhav HR. Histamine H3 receptor function and ligands: recent developments. Mini Rev Med Chem 2013;13:47-57
   PubMed Web of Science ®Google Scholar
• Sander K, von Coburg Y, Camelin JC, et al. Acidic elements in histamine H3 receptor antagonists. Bioorg Med Chem Lett 2010;20:1581-4
   PubMed Web of Science ®Google Scholar
• Apodaca R, Dvorak CA, Xiao W, et al. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. J Med Chem 2003;46:3938-44
   PubMed Web of Science ®Google Scholar
• Sander K, Kottke T, Hoffend C, et al. First metal-containing histamine H3 receptor ligands. Org Lett 2010;12:2578-81
   PubMed Web of Science ®Google Scholar
• Łażewska D, Kieć-Kononowicz K. Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Patents 2010;20:1147-69
   PubMed Web of Science ®Google Scholar
• Rodríguez Sarmiento RM, Nettekoven MH, Taylor S, et al. Selective naphthalene H3 receptor inverse agonists with reduced potential to induce phospholipidosis and their quinoline analogs. Bioorg Med Chem Lett 2009;19:4495-500
   PubMed Web of Science ®Google Scholar
• Black LA, Liu H, Diaz GJ, et al. Minimization of potential hERG liability in histamine H3 receptor antagonists. Inflamm Res 2008;57(Suppl 1):S45-6
   PubMedGoogle Scholar
• Davenport AJ, Moller C, Heifetz A, et al. Using electrophysiology and in silico three-dimential modeling to reduce human ether-a-go-go related gene K+ channel inhibition in a histamine H3 receptor antagonist program. Assay Drug Dev Technol 2010;8:781-9
   PubMed Web of Science ®Google Scholar
• Levoin N, Labeeuw O, Calmels T, et al. Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity. Bioorg Med Chem Lett 2011;21:5378-83
   PubMed Web of Science ®Google Scholar
• Kuhne S, Wijtmans M, Lim HD, et al. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 2011;20:1629-48
   PubMed Web of Science ®Google Scholar
• A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia (COMPLETED). NCT00888693. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and safety study of ABT-288 in subjects with mild-to-moderate Alzheimer's Disease (COMPLETED). NCT01018875. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and safety study for cognitive deficits in adult subjects with schizophrenia. (COMPLETED). NCT01077700. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain (COMPLETED). NCT01579279. 2012. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A study of ABT-652 in adults with osteoarthritis pain of the knee. (COMPLETED). NCT01207115. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Safety, tolerability, pharmacokinetic and pharmacodynamics study of ABT-652 in subjects with excessive daytime sleepiness (COMPLETED). NCT01124851. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A study of ABT-652 in combination with a nonsteroidal anti-inflammatory drug (NSID) in adults with osteoarthritis pain of the knee. (COMPLETED). NCT01444365. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Single-dose safety study of APD916 in healthy volunteers (COMPLETED). NCT01093508. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration (COMPLETED). NCT01194986. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects (COMPLETED). NCT01121302. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects (COMPLETED). NCT01171105. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment (COMPLETED). NCT01548287. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects (COMPLETED). NCT01335451. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder. NOT YET RECRUITING. NCT01904773. 2013. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy (Harmony2). (COMPLETED). NCT01067235. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients. (COMPLETED). NCT00642928. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. (COMPLETED). NCT01638403. 2012. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease (HARPS2) (COMPLETED). NCT01066442. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease (HARPS1) (COMPLETED). NCT01036139. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study to Demonstrate Cognitive Enhancing Effects of BF2.649. (COMPLETED). NCT00690274. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) (RECRUITING). NCT01789398. 2013. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) (COMPLETED). NCT01620554. 2012. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP. (HAROSA2). (ONGOING). NCT01072968. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy (Harmony1) (COMPLETED). NCT01067222. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) (HARMONYIII). (ONGOING). NCT01399606. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS (HAROSA1). (ONGOING). NCT01071876. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Pharmacokinetics of BF2.649 in Renal Impairment. (COMPLETED). NCT01619033. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP). (RECRUITING). NCT01800045. 2013. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects. (NOT YET RECRUITING). NCT01903824. 2013. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers. (COMPLETED). NCT00387413. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy. (TERMINATED). NCT00366080. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• An Imaging Study to Investigate the Distribution of GSK239512 in the Brain. (COMPLETED). NCT00474513. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease. (COMPLETED). NCT00675090. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis. ((RECRUITING). NCT01772199. 2013. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia. (COMPLETED). NCT01009060. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• GSK239512 DDI Study. (C OMPLETED). NCT01802931. 2013. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• An Imaging Study to Investigate the Distribution of GSK239512 in the Brain. (COMPLETED). NCT00474513. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease. (COMPLETED). NCT01009255. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo. (COMPLETED). NCT00851344. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• 723/726 Proof of Concept Study in Allergen Challenge Chamber in Hannover. (COMPLETED). NCT00972504. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects. (COMPLETED). NCT00605852. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo. (COMPLETED). NCT00824356. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male Subjects. (COMPLETED). NCT00694993. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects. (ONGOING). NCT01540864. 2012. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy. (COMPLETED). NCT00424931. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder. (COMPLETED). NCT00566449. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers. (COMPLETED). NCT00915434. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers. (COMPLETED). NCT00915746. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD). (COMPLETED). NCT00880217. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD). (COMPLETED). NCT00890240. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD). (COMPLETED). NCT00890292. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers. (COMPLETED). NCT01159821. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Safety and Efficacy of JNJ-39220675 in Participants With Allergic Rhinitis. (COMPLETED). NCT00804687. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED). NCT00475735. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Evaluate the Effects of MK0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (TERMINATED). NCT00874939. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)(COMPLETED). NCT00420420. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015). (TERMINATED). NCT00620659. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) (COMPLETED). NCT00506077. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs. (COMPLETED). NCT00887601. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Placebo-Controlled Crossover Study to Evaluate Donepezil and MK-3134 for Reversal of Cognitive Impairment Associated With Scopolamine Administration (3134-005)(COMPLETED). NCT01181310. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010) (COMPLETED). NCT01110616. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD). (COMPLETED). NCT00531752. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Phase I, Healthy Volunteer Positron Emission Tomography Study. (COMPLETED). NCT00730990. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease. (COMPLETED). NCT01028911. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome. (TERMINATED). NCT01475383. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Add On Treatment for Cognitive Deficits in Schizophrenia. (COMPLETED). NCT01346163. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy. (COMPLETED). NCT01006122. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge. (COMPLETED). NCT00562120. 2007. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis. (COMPLETED). NCT01033396. 2009. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects. (TERMINATED). NCT01298505. 2011. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and safety of S 38093 versus placebo in patients with mild to moderate Alzheimer's disease. (ONGOING). ISRCTN89039808. 2011. Available from: www.controlled-trials.com [Last accessed 30 July 2013]
   Google Scholar
• Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil. (COMPLETED). NCT01266525. 2010. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Subjects (Study P05483) (COMPLETED). NCT00642993. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338AM1)(COMPLETED). NCT00673465. 2008. Available from: www.ClinicalTrials.gov [Last accessed 30 July 2013]
   Google Scholar
• Othman AA, Haig G, Florian H, et al. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers. Br J Clin Pharmacol 2013;75:1299-311
   PubMed Web of Science ®Google Scholar
• Jucaite A, Takano A, Boström E, et al. AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol 2013;16:1231-9
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité D, Parain D, Genton P, et al. Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model. Epilepsy Behav 2013;28:66-70
   PubMed Web of Science ®Google Scholar
• Inocente C, Arnulf I, Bastuji H, et al. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 2012;35:55-60
   PubMed Web of Science ®Google Scholar
• Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011;163:713-12
   PubMed Web of Science ®Google Scholar
• Nathan PJ, Boardley R, Scott N, et al. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr Alzheimer Res 2013;10:240-51
   PubMed Web of Science ®Google Scholar
• Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H1/H3 receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol 2012;158:84-98
   PubMed Web of Science ®Google Scholar
• Weisler RH, Pandina GJ, Daly EJ, et al. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 2012;26:421-34
   PubMed Web of Science ®Google Scholar
• Barchuk WT, Salapatek AM, Ge T, et al. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol 2013; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Egan FM, Zhao X, Gottwald R, et al. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr Res 2013;146:224-30
   PubMed Web of Science ®Google Scholar
• Herring WJ, Wilens TE, Adler LA, et al. Randomized controlled study of the histamine H3 inverse agonist MK-0249 in adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73:e891-8
   PubMedGoogle Scholar
• Egan M, Yaari R, Liu L, et al. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr Alzheimer Res 2012;9:481-90
   PubMed Web of Science ®Google Scholar
• Zoethout RW, Iannone R, Bloem BR, et al. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. J Psychopharmacol 2012;26:292-302
   PubMed Web of Science ®Google Scholar
• James LM, Iannone R, Palcza J, et al. Effect of a novel histamine subtype-3 receptor inverse agonist and modafinil on EEG power spectra during sleep deprivation and recovery sleep in male volunteers. Psychopharmacology (Berl) 2011;215:643-53
   PubMed Web of Science ®Google Scholar
• Herring WJ, Liu K, Hutzelmann J, et al. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study. Sleep Med 2013;14:955-63
   PubMed Web of Science ®Google Scholar
• Cho W, Maruff P, Connell J, et al. Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl) 2011;218:513-24
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA Jr, Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012;129:409-12
   PubMed Web of Science ®Google Scholar
• Available from: http://invest.arenapharm.com/releasedetail.cfm?releaseid=520672 [Last accessed on 10 September 2013]
   Google Scholar
• Esbenshade TA, Browman KE, Miller TR, et al. Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 2012;343:233-45
   PubMed Web of Science ®Google Scholar
• Hudzik TJ, Basso A, Boyce-Rustay JM, et al. Assessment of the abuse liability of ABT-288, a novel histamine. H3 receptor antagonist. Psychopharmacology (Berl) 2013;228:187-97
   PubMed Web of Science ®Google Scholar
• Semple G, Santora VJ, Smith JM, et al. Identification of biaryl sulfone derivatives as antagonists of the histamine H3 receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916). Bioorg Med Chem Lett 2012;22:71-5
   PubMed Web of Science ®Google Scholar
• Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol 2013;169:632-44
   PubMed Web of Science ®Google Scholar
• Brabant C, Charlier Y, Tirelli E. The histamine H3-receptor inverse agonist Pitolisant improves fear memory in mice. Behav Brain Res 2013;243:199-204
   PubMed Web of Science ®Google Scholar
• Zhang DD, Sisignano M, Schuh CD, et al. Overdose of the histamine H3 inverse agonist pitolisant increases thermal pain thresholds. Inflamm Res 2012;61:1283-91
   PubMed Web of Science ®Google Scholar
• Hudkins RL, Raddatz R, Tao M, et al. Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. J Med Chem 2011;54:4781-92
   PubMed Web of Science ®Google Scholar
• Raddatz R, Hudkins RL, Mathiasen JR, et al. CEP-26401 (irdabisant), a potent and selective histamine H3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther 2012;340:124-33
   PubMed Web of Science ®Google Scholar
• Salinas C, Weinzimmer D, Searle G, et al. Kinetic analysis of drug-target interactions with PET for characterization of pharmacological hysteresis. J Cereb Blood Flow Metab 2013;33:700-7
   PubMed Web of Science ®Google Scholar
• McGaraughty S, Chu KL, Cowart MD, Brioni JD. Antagonism of supraspinal histamine H3 receptors modulates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther 2012;343:13-20
   PubMed Web of Science ®Google Scholar
• Hsieh GC, Honore P, Pai M, et al. Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res 2010;1354:74-84
   PubMed Web of Science ®Google Scholar
• Giannoni P, Medhurst AD, Passani MB, et al. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 2010;332:164-72
   PubMed Web of Science ®Google Scholar
• Slack RJ, Russell LJ, Hall DA, et al. Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H1 and H3 receptors. Br J Pharmacol 2011;164:1627-41
   PubMed Web of Science ®Google Scholar
• Galici R, Rezvani AH, Aluisio L, et al. JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl) 2011;214:829-41
   PubMed Web of Science ®Google Scholar
• Wager TT, Pettersen BA, Schmidt AW, et al. Discovery of two clinical histamine H3 receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl] cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764). J Med Chem 2011;54:7602-20
   PubMed Web of Science ®Google Scholar
• Griebel G, Decobert M, Jacquet A, Beeské S. Awakening properties of newly discovered highly selective H3 receptor antagonists in rats. Behav Brain Res 2012;232:416-20
   PubMed Web of Science ®Google Scholar
• Griebel G, Pichat P, Pruniaux MP, et al. SAR110894, a potent histamine H3-receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav 2012;102:203-14
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ncbi.nlm.nih.gov/pubmed/
   Google Scholar
• Cowart M, Hsieh G, Black LA, et al. Pharmacological characterization of A-960656, a histamine H3 receptor antagonist with efficacy in animal models of osteoarthritis and neuropathic pain. Eur J Pharmacol 2012;684:87-94
   PubMed Web of Science ®Google Scholar
• Lunn G, Mowbray CE, Liu WLS, et al. The discovery an profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis. MedChemMed 2012;3:339-43
   Web of Science ®Google Scholar
• Chen PY, Tsai CT, Ou CY, et al. Computational analysis of novel drugs designed for use as acetylcholinesterase inhibitors and histamine H3 receptor antagonists for Alzheimer's disease by docking, scoring and de novo evolution. Mol Med Rep 2012;5:1043-8
   PubMed Web of Science ®Google Scholar
• Huang W, Tang L, Shi Y, et al. Searching for the multi-target-directed ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities. Bioorg Med Chem 2011;19:7158-67
   PubMed Web of Science ®Google Scholar
• Bajda M, Kuder KJ, Łażewska D, et al. Dual-acting diether derivatives of piperidine and homopiperidine with histamine H3 receptor antagonistic and anticholinesterase activity. Arch Pharm (Weinheim) 2012;345:591-7
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Browning C, Buckley JM, et al. The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem 2011;54:2183-95
   PubMed Web of Science ®Google Scholar
• Altenbach RJ, Black LA, Strakhova MI, et al. Diaryldiamines with dual inhibition of the histamine H3 receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain. J Med Chem 2010;53:7869-73
   PubMed Web of Science ®Google Scholar
• Selivanova SV, Honer M, Combe F, et al. Radiofluorinated histamine H3 receptor antagonist as a potential probe for in vivo PET imaging: radiosynthesis and pharmacological evaluation. Bioorg Med Chem 2012;20:2889-96
   PubMed Web of Science ®Google Scholar
• Bao X, Lu S, Liow JS, et al. Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype. J Med Chem 2012;55:2406-15
   PubMed Web of Science ®Google Scholar
• Wang M, Gao M, Steele BL, et al. A new facile synthetic route to [11C]GSK189254, a selective PET radioligand for imaging of CNS histamine H3 receptor. Bioorg Med Chem Lett 2012;22:4713-18
   PubMed Web of Science ®Google Scholar
• Ashworth S, Rabiner EA, Gunn RN, et al. Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET. J Nucl Med 2010;51:1021-9
   PubMed Web of Science ®Google Scholar
• Kuder K, Kiec-Kononowicz K. Fluorescent GPCR ligands as new tools in pharmacology. Curr Med Chem 2008;15:2132-43
   PubMed Web of Science ®Google Scholar
• Kuder KJ, Kottke T, Stark H, et al. Search for novel, high affinity histamine H3 receptor ligands with fluorescent properties. Inflamm Res 2010;59(S2):S247-8
   Google Scholar
• Tomasch M, Schwed JS, Weizel L, Stark H. Novel chalone-based fluorescent human histamine H3 receptor ligands as pharmacological tools. Front Syst Neurosci 2012;6:14
   PubMedGoogle Scholar
• Ellenbroek BA. Histamine H3 receptors, the complex interaction with dopamine and its implications for addiction. Br J Pharmacol 2013;170:46-57
   PubMed Web of Science ®Google Scholar
• Available from: http://worldwide.espacenet.com/
   Google Scholar
• Schering Corp. Tricyclic heterocycle derivatives as histamine H3 antagonists. WO2010011653; 2010
   Google Scholar
• Schering Corp. Bicyclic heterocycle derivatives as histamine H3 receptor antagonists. WO2010011657; 2010
   Google Scholar
• Schering Corp. Piperidine derivatives useful as histamine H3 antagonists. WO2007001975; 2007
   Google Scholar
• Schering Corp. Substituted aniline derivatives useful as histamine H3 antagonists. WO2007075688; 2007
   Google Scholar
• Suven Life Sciences Ltd. Novel compounds as histamine H3 receptor ligands. WO2012114348; 2012
   Google Scholar
• Suven Life Sciences Ltd. Heterocyclyl compounds as histamine H3 receptor ligands. WO2012029070; 2012
   Google Scholar
• Evotec Neurosciences GMBH. Tetrahydronaphthyridines and aza derivatives thereof as histamine H3 receptor antagonists. WO2009121812; 2009
   Google Scholar
• Evotec Neurosciences GMBH. Acyl- and sulfonyl tetrahydronaphthyridines and aza derivatives thereof as histamine H3 receptor anatagonists. WO2010026113; 2010
   Google Scholar
• Evotec Neurosciences GMBH. (dihydro)naphthyridinone derivatives as histamine H3 receptor anatagonists. WO2010052222; 2010
   Google Scholar
• Sepracor, Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof. WO2010144571; 2010
   Google Scholar
• Takeda Pharmaceutical. Compounds and their use to treat histamine H3 related disorders. WO2013027001; 2013
   Google Scholar
• Evotec AG. Piperazine and aminopyrrolidine compounds as histamine H3 receptor antagonists. WO2010133544; 2010
   Google Scholar
• Evotec Neurosciences GMBH. Diazepanes as histamine H3 receptor antagonist. WO2009095394; 2009
   Google Scholar
• Cephalon, Inc. Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands. WO2011002984; 2011
   Google Scholar
• Les Laboratoires Servier. Azabicyclo[3.2.0]hept-6-yl derivatives as antagonists of histamine H3 receptor. WO2011070252; 2011
   Google Scholar
• Les Laboratoires Servier. Azabicyclic compounds, a process for their preparation and pharmaceutical composition containing them. US20090312389; 2009
   Google Scholar
• Richter Gedeon NYRT. Histamine H3 antagonist steroidal carboxamides. WO2013027073; 2013
   Google Scholar
• Glaxo Group Ltd. Quinoline derivatives to treat inflammatory and allergic diseases. WO2009050204; 2009
   Google Scholar
• Glaxo Group Ltd. Quinoline derivatives and their uses for rhinitis and urticarial. WO2010094643; 2010
   Google Scholar
• Glaxo Group Ltd. 2-Substituted 4-benzylphthalazinone derivatives as histamine H1 and H3 antagonists. WO2007122156; 2007
   Google Scholar
• Norman P. New H1/H3 antagonists for treating allergic rhinitis: WO2010094643. Expert Opin Ther Patents 2011;21:425-9
   PubMed Web of Science ®Google Scholar
• AstraZeneca Pharmaceuticals LP. Cyclopropyl amide derivatives 978. WO2009024823; 2009
   Google Scholar
• AstraZeneca AB. Cyclopropyl amide derivatives targeting the histamine H3 receptor. WO2010096011; 2010
   Google Scholar
• AstraZeneca AB. Processes for making cyclopropyl amide derivatives and intermediates associated therewith. WO2011102794; 2011
   Google Scholar
• AstraZeneca AB. Spirocyclopropyl piperidine derivatives. WO2008147314; 2008
   Google Scholar
• AstraZeneca AB. Spirocyclobutyl piperidine derivatives. WO2010062245; 2010
   Google Scholar
• Evotec Neurosciences GMBH. Azetidines and cyclobutanes as histamine H3 receptor antagonists. WO2009135842; 2009
   Google Scholar
• Evotec Neurosciences GMBH. Azetidines as histamine H3 receptor antagonists. WO2010086403; 2010
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Phenyl sulfonyl derivatives and their use as histamine H3 antagonists. WO2011121309; 2011
   Google Scholar
• Takeda Pharmaceutical Co. Ltd. Benzazepine derivatives and their use as histamine H3 antagonists. WO2010007382; 2010
   Google Scholar
• Sepracor, Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof. WO2010093425; 2010
   Google Scholar
• Sepracor, Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof. WO2011031816; 2011
   Google Scholar
• Sepracor, Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof. WO2011031818; 2011
   Google Scholar
• Janssen Pharmaceutica NV. Process for the preparation of histamine H3 receptor modulators. WO2010107897; 2010
   Google Scholar
• Sanofi-Aventis. Novel fumarate salts of a histamine H3 receptor antagonist. WO2010151611; 2010
   Google Scholar
• Sanofi-Aventis. Process of preparation 2-(cyclohexylmethyl)-N-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide. WO2011109675; 2011
   Google Scholar
• Sanofi-Aventis. Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics. WO2005118547; 2005
   Google Scholar
• Abbott Lab. Processes for preparing 1,2-substituted cyclopropyl derivatives. WO2012037258; 2012
   Google Scholar
• AstraZeneca AB. Solid forms comprising a cyclopropyl amide derivatives. WO2011102793; 2011
   Google Scholar
• AstraZeneca AB. New crystalline form of a cyclopropyl benzamide derivative. WO2011102795; 2011
   Google Scholar
• Abbott Lab. Cyclopropylamine derivatives. WO2007150010; 2007
   Google Scholar
• Abbott Lab. Cyclopropylamine derivatives. WO2009079225; 2009
   Google Scholar
• Abbott Lab. Treatment of osteoarthritis pain. WO2010129242; 2010
   Google Scholar
• Zhao C, Sun M, Bennani YL, et al. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem 2008;51:5423-30
   PubMed Web of Science ®Google Scholar
• Santora VJ, Covel JA, Hayashi R, et al. A new family of H3 receptor antagonists based on the natural product Conessine. Bioorg Med Chem Lett 2008;18:1490-4
   PubMed Web of Science ®Google Scholar
• Hough LB. Genomic meets histamine receptors: new subtypes, new receptors. Mol Pharmacol 2001;59:415-19
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ziarcopharma.com/h3.html
   Google Scholar
• Jayaranjan P, Shanmuganathan D, Jabaris SL, et al. SUVEN-G1031, a novel selective H3 receptor antagonist in animal models of cognitive deficits. Alzheimers Demen 2011;7:S796
   Google Scholar
• Hsieh CG, Chandran P, Salyers AK, et al. H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic models in rats. Pharmacol Biochem Behav 2010;95:41-50
   PubMed Web of Science ®Google Scholar